Reuters Photojournalism
Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography. See more | Photo caption
Ethiopia's salt trails
For centuries merchants have traveled to Ethiopia to collect salt from the surface of the vast desert basin. Slideshow
Sponsored Links
UCB says had positive trial for Vimpat as monotherapy
The logo of Belgian drugmaker UCB is seen at the entrance of the company's headquarters in Brussels March 2, 2011.
Credit: Reuters/Yves Herman
BRUSSELS |
BRUSSELS (Reuters) - Belgian pharmaceutical company UCB said on Tuesday its new epilepsy treatment Vimpat had produced promising results in a Phase III trial into its use without other drugs.
UCB said it would to submit the data as part of a supplementary new drug application for lacosamide, marketed as Vimpat, to the U.S. Food and Drug Administration. The application is planned in the second half of 2013.
Vimpat is approved as an adjunctive therapy for the treatment of partial-onset seizures in adults with epilepsy, but not as a monotherapy.
(Reporting by Philip Blenkinsop)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Follow Reuters